Betta Pharmaceuticals Co., Ltd. Quarterly Results: Standalone & Consolidated Reports

Quarterly Results

Results Snapshot

YoYQoQ

Figures in Million

Consolidate Quarterly Results

Sep'25

Jun'25

Mar'25

Dec'24

Sep'24

Jun'24

Mar'24

Net Sales

985.93

813.86

917.55

547.31

843.88

764.99

735.78

Other Operating Income

0.00

Total Operating income

985.93

813.86

917.55

547.31

843.88

764.99

735.78

Raw Material Cost

208.48

240.40

258.17

204.40

182.97

154.75

169.57

Purchase of Finished goods

0.00

(Increase) / Decrease In Stocks

0.00

Employee Cost

0.00

Power Cost

0.00

Manufacturing Expenses

18.62

17.24

21.65

13.94

9.27

11.27

11.01

Selling and Distribution Expenses

449.03

363.23

336.65

164.00

395.93

360.73

312.99

Other Expenses

9.97

11.36

8.11

9.26

10.71

7.84

12.79

Total Expenditure (Excl Depreciation)

775.82

734.48

697.61

474.92

695.31

605.13

621.43

Operating Profit (PBDIT) excl Other Income

210.10000000000002

79.4

219.89999999999998

72.4

148.6

159.9

114.3

Other Income

-0.84

13.84

16.16

2.47

2.04

11.15

Operating Profit (PBDIT)

197.80

220.22

360.11

156.89

248.00

241.05

204.28

Interest

18.62

17.24

21.65

13.94

9.27

11.27

11.01

Exceptional Items

27.99

0.58

-76.60

-73.12

46.81

0.00

Gross Profit (PBDT)

777.45

573.46

659.38

342.91

660.91

610.24

566.21

Depreciation

0.00

135.55

102.09

83.90

Profit Before Tax

207.16

68.01

126.31

-32.26

183.45

145.89

109.38

Tax

31.46

29.42

27.69

-19.49

-7.29

20.52

13.44

Provisions and contingencies

0.00

Profit After Tax

177.04

39.81

100.09

-13.66

192.28

125.81

98.14

Extraordinary Items

0.00

Prior Period Expenses

0.00

Other Adjustments

0.00

Net Profit

177.04

39.81

100.09

-13.66

192.28

125.81

98.14

Share in Profit of Associates

0.00

Minority Interest

-4.74

-4.56

-4.63

-4.52

-3.25

-3.47

-4.35

Other related items

0.00

Consolidated Net Profit

172.30

35.24

95.46

-18.17

189.03

122.33

93.79

Equity Capital

0.00

Face Value

1.0

Reserves

5,843.40

5,594.36

5,543.68

5,573.81

5,636.95

5,471.68

5,522.18

Earnings per share (EPS)

0.42

0.09

0.24

-0.03

0.46

0.3

0.23

Diluted Earnings per share

0.42

0.09

0.24

-0.03

0.46

0.3

0.23

Operating Profit Margin (Excl OI)

20.15%

8.7%

22.71%

7.06%

17.0%

20.28%

14.85%

Gross Profit Margin

21.01%

25.01%

28.54%

12.76%

33.84%

30.04%

26.27%

PAT Margin

17.96%

4.89%

10.91%

-2.5%

22.79%

16.45%

13.34%

Public Share Holdings (%)

0.0%

Pledged Promotor Holding (%)

0.0%

Quarterly Analysis Highlights - QoQ

Net Sales

QoQ Growth in quarter ended Sep 2025 is 21.13% vs -11.30% in Jun 2025

Consolidate Net Profit

QoQ Growth in quarter ended Sep 2025 is 389.49% vs -63.14% in Jun 2025

Operating Profit (PBDIT) excl Other Income

QoQ Growth in quarter ended Sep 2025 is -3.78% vs -40.00% in Jun 2025

Interest

QoQ Growth in quarter ended Sep 2025 is 8.14% vs -20.37% in Jun 2025

Operating Profit Margin (Excl OI)

QoQ Growth in quarter ended Sep 2025 has improved from Jun 2025

Compare Quarterly Results Of Betta Pharmaceuticals Co., Ltd. With

Select Peers

Figures in Million

Consolidate Quarterly Results

Change(CNY)

Change(%)

Net Sales

985.93

Other Operating Income

0.00

Total Operating income

985.93

Raw Material Cost

208.48

Purchase of Finished goods

0.00

(Increase) / Decrease In Stocks

0.00

Employee Cost

0.00

Power Cost

0.00

Manufacturing Expenses

18.62

Selling and Distribution Expenses

449.03

Other Expenses

9.97

0.00

9.97

Total Expenditure (Excl Depreciation)

775.82

Operating Profit (PBDIT) excl Other Income

210.11

0.00

210.11

Other Income

-0.84

Operating Profit (PBDIT)

197.80

Interest

18.62

Exceptional Items

27.99

Gross Profit (PBDT)

777.45

Depreciation

0.00

Profit Before Tax

207.16

Tax

31.46

Provisions and contingencies

0.00

Profit After Tax

177.04

Extraordinary Items

0.00

Prior Period Expenses

0.00

Other Adjustments

0.00

Net Profit

177.04

Share in Profit of Associates

0.00

Minority Interest

-4.74

Other related items

0.00

Consolidated Net Profit

172.30

Equity Capital

0.00

Face Value

1.00

0.00

Reserves

5,843.40

Earnings per share (EPS)

0.42

Diluted Earnings per share

0.42

Operating Profit Margin (Excl OI)

20.15%

0.00

20.15%

Gross Profit Margin

21.01%

0.00

21.01%

PAT Margin

17.96%

0.00

17.96%

Public Share Holdings (%)

0.00

0.00%

Pledged Promotor Holding (%)

0.00

0.00%

Quarterly - Net Sales

Net Sales 98.59 Million

in Sep 2025

Figures in Million

QoQ Growth in quarter ended Sep 2025 is 21.13% vs -11.30% in Jun 2025

YoY Growth in quarter ended Sep 2025 is 16.83% vs 15.65% in Sep 2024

Quarterly - Consolidate Net Profit

Consolidate Net Profit 17.23 Million

in Sep 2025

Figures in Million

QoQ Growth in quarter ended Sep 2025 is 389.49% vs -63.14% in Jun 2025

YoY Growth in quarter ended Sep 2025 is -8.84% vs 23.93% in Sep 2024

Quarterly - Operating Profit (PBDIT)

Operating Profit (PBDIT) 19.86 Million

in Sep 2025

Figures in Million

QoQ Growth in quarter ended Sep 2025 is -3.78% vs -40.00% in Jun 2025

YoY Growth in quarter ended Sep 2025 is -19.10% vs 1.61% in Sep 2024

Quarterly - Interest

Interest 1.86 Million

in Sep 2025

Figures in Million

QoQ Growth in quarter ended Sep 2025 is 8.14% vs -20.37% in Jun 2025

YoY Growth in quarter ended Sep 2025 is 100.00% vs -23.77% in Sep 2024

Quarterly - Operating Profit Margin (Excl OI)

Operating Profit Margin (Excl OI) 20.15%

in Sep 2025

Figures in %

QoQ Growth in quarter ended Sep 2025 has improved from Jun 2025

YoY Growth in quarter ended Sep 2025 has improved from Sep 2024